As efficacy of stimulants and other ADHD medication has not been shown in randomized trials yet, the efficacy of the current medication options is at least controversial.
The result of this process should personalize treatment where goals and medication options are based on individual factors such as age, duration of the disease, presence or absence of diabetes complications, underlying pathophysiology, and risk/benefit of each medication and their combination.
The incremental costs per QALYs gained were consistently lower when atomoxetine was compared to 'no medication', although 'no medication' option was associated with 'zero costs'.
For participants who declined medication, the options were: "Too small effect of the medication", "Wish to avoid side-effects", "Do not want the extra expense", "Dislike taking medication", "Find the information difficult to understand", "Prefer to change lifestyle", and "General disbelief in effectiveness of medication".
To assess lifetime experience of a serious problem or side effect from treatment, parents were asked: "Has your child ever experienced a serious problem or side effect from a prescription medication?" Response options were yes/no.
For participants who accepted medication, the options were: "For health reasons", "Trust in my GP" or "Responsibility towards my family".
Proponents believe there are combination medication options that are appropriate for patients suffering treatment-resistant depression (TRD) [ 25].
Given a choice between the two medication options, respondents were asked to indicate which medication they would prefer to continue taking.
The medication inquiry system response options were as follows: (1) safe in CKD, (2) not safe in CKD, (3) use with caution/speak with your health care provider, or (4) error message (for an incorrectly inputted medication).
